Purchasing new hardware? Read our latest product comparisons

Researchers engineer red blood cells to deliver therapeutic payloads


July 3, 2014

Modified red blood cells could be put to work, delivering more than just oxygen

Modified red blood cells could be put to work, delivering more than just oxygen

Although several studies are currently exploring the use of man-made nanoparticles for delivering medication to targeted areas of the body, care must be taken to ensure that those particles don't cause adverse reactions when introduced to the bloodstream. Scientists at the MIT-affiliated Whitehead Institute, however, are taking a different approach to the same basic concept. They've developed a method of attaching chemical payloads to red blood cells.

Besides their being unlikely to get attacked by the immune system or cause toxic reactions, red blood cells (RBCs) are also a good choice due to the facts that they're the most abundant type of cell in the human body, and they can live for up to 120 days in circulation. Additionally, because RBCs lose their genetic material upon maturation, their introduction isn't likely to cause problems such as tumor formation.

Led by professors Harvey Lodish and Hidde Ploegh, the researchers started by genetically manipulating early-stage RBC progenitor cells, to produce proteins on their outer surface. As those cells matured into proper RBCs and lost their genetic material, the proteins nonetheless stayed intact.

In a process known as "sortagging," the scientists then used the bacterial enzyme sortase A to create a bond between those proteins and a substance of their choice – that substance could include any number of medications, or antibodies that could bind with toxins present in the body.

It is hoped that once developed further, the technique could be used for things like removing harmful cholesterol from the bloodstream, carrying clot-busting proteins to blocked blood vessels, delivering anti-inflammatory antibodies to sites of inflammation, or to suppress unwanted immune responses to protein-based therapies.

DARPA (the Defense Advanced Research Projects Agency) is funding the project, as it may also have applications in the development of treatments or vaccines for biological weapons.

Source: Whitehead Institute

About the Author
Ben Coxworth An experienced freelance writer, videographer and television producer, Ben's interest in all forms of innovation is particularly fanatical when it comes to human-powered transportation, film-making gear, environmentally-friendly technologies and anything that's designed to go underwater. He lives in Edmonton, Alberta, where he spends a lot of time going over the handlebars of his mountain bike, hanging out in off-leash parks, and wishing the Pacific Ocean wasn't so far away. All articles by Ben Coxworth
Post a Comment

Login with your Gizmag account:

Related Articles
Looking for something? Search our articles